Trials / Completed
CompletedNCT06548815
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
A Single-center, Single-administration, Randomized, Placebo-controlled, Dose-escalation Trial Evaluated the Safety, Tolerability, PK, and PD Parameters of GZR4 in Healthy Male Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Gan and Lee Pharmaceuticals, USA · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR4 | Ascending single doses - 4 dose levels. |
| DRUG | Placebo | Ascending single doses - 4 dose levels. |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2023-03-24
- Completion
- 2023-03-24
- First posted
- 2024-08-12
- Last updated
- 2024-08-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06548815. Inclusion in this directory is not an endorsement.